Melanoma Clinical Trials in Arizona

Showing 121-140 of 238 trials

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

NCT04282044

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with monotherapy dose escalation followed by combination cohorts.

Solid Tumor, AdultTriple Negative Breast CancerColorectal Cancer+6 more

BioEclipse Therapeutics60 participantsStarted Jan 2021

Scottsdale, Arizona, United States • La Jolla, California, United States • Stanford, California, United States

UNKNOWNPhase 1/231 miles

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.

CancerTumor, SolidMalignant Neoplasm+7 more

OncoResponse, Inc.172 participantsStarted Sep 2021

Scottsdale, Arizona, United States • Austin, Texas, United States • San Antonio, Texas, United States

PreviousPage 7 of 12Next

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Melanoma Trials in Other Cities

Safety Study of SEA-CD40 in Cancer Patients

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Study in Subjects With Small Primary Choroidal Melanoma

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Other Conditions in Arizona